Results 91 to 100 of about 61,341 (287)

Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Spironolactone may have prognostic benefit in selected patients with heart failure with preserved ejection fraction. This study assessed the myocardial tissue effects of spironolactone in heart failure with preserved ejection fraction. Methods
Adam K. McDiarmid, Peter P. Swoboda, Bara Erhayiem, Katrina A. Bounford, Petra Bijsterveld, Keith Tyndall, Graham J. Fent, Pankaj Garg, Laura E. Dobson, Tarique A. Musa, James R. J. Foley, Klaus K. Witte, Mark T. Kearney, John P. Greenwood, Sven Plein   +14 more
doaj   +1 more source

Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?

Journal of Cardiovascular Pharmacology, 2020
The high mortality of specific groups from COVID-19 highlights the importance of host-viral interactions and the potential benefits from enhancing host defenses.
C. Wilcox, B. Pitt
semanticscholar   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.

PLoS ONE
ObjectiveTo characterize the dose-exposure-response effect of spironolactone on biomarkers of the classical and alternative arms of the renin-angiotensin-aldosterone system (RAAS) in healthy dogs.AnimalsTen healthy purpose-bred Beagle dogs ...
Allison K Masters, Jessica L Ward, Emilie Guillot, Oliver Domenig, Lingnan Yuan, Jonathan P Mochel   +5 more
doaj   +1 more source

Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial

European Journal of Heart Failure, 2020
In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA‐HF), high‐dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low‐dose spironolactone (25 mg daily ...
S. Denus, Grégoire Leclair, M. Dubé, Isabelle St‐Jean, Y. F. Zada, Essaïd Oussaïd, Martin Jutras, M. Givertz, R. Mentz, W. Tang, J. Ferreira, J. Rouleau, J. Butler, A. Kalogeropoulos   +13 more
semanticscholar   +1 more source

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
Background Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist ...
E. Shantsila, F. Shahid, Yongzhong Sun, J. Deeks, M. Calvert, J. Fisher, P. Kirchhof, P. Gill, G. Lip   +8 more
semanticscholar   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Effect of spironolactone on pain responses in mice [PDF]

, 2010
The effects of spironolactone, a non-selective aldosterone antagonist, were examined on thermally-induced pain using the hot-plate and tail-flick tests, on hemogenic pain induced by intraplantar capsaicin, on electrically-induced pain, on visceral ...
Abdel-Salam, Omar M.E., Baiuomy, Ayman R., Nada, Somaia A.   +2 more
core  

Adapting clinical guidelines to take account of multimorbidity [PDF]

, 2012
Most people with a chronic condition have multimorbidity, but clinical guidelines almost entirely focus on single conditions. It will never be possible to have good evidence for every possible combination of conditions, but guidelines could be made more ...
Alderson, P., Guthrie, B., McMurdo, M.E.T., Mercer, S.W., Payne, K.   +4 more
core   +1 more source